Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk

被引:67
作者
Gsur, A [1 ]
Preyer, M
Haidinger, G
Zidek, T
Madersbacher, S
Schatzl, G
Marberger, M
Vutuc, C
Micksche, M
机构
[1] Univ Vienna, Inst Canc Res, Div Appl & Expt Oncol, A-1010 Vienna, Austria
[2] Univ Vienna, Inst Canc Res, Div Epidemiol, A-1010 Vienna, Austria
[3] Univ Vienna, Dept Urol, Div Epidemiol, A-1010 Vienna, Austria
关键词
D O I
10.1093/carcin/23.10.1647
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As the development of prostate cancer is androgen-dependent, it has been hypothesized that variation in transcriptional activity by the androgen receptor (AR) related to polymorphic CAG repeats in exon 1, influences prostate cancer risk. The AR regulates gene transcription by binding to androgen-response elements (AREs) in target genes, such as the prostate-specific antigen (PSA). In the ARE-I sequence of the PSA gene an adenine to guanine polymorphism is described. It has been hypothesized that the AR binds the two PSA alleles (A and G) with differing affinities and may, thereby, differentially influence prostate cancer risk. To examine the role of the polymorphisms in the AR and PSA genes in prostate cancer susceptibility, we conducted a case-control study of Austrian Caucasians with 190 newly diagnosed prostate cancer patients and 190 age-matched control men with benign prostatic hyperplasia (BPH). The polymorphisms were determined by polymerase chain reaction (PCR)-based methods using DNA from peripheral white blood cells. Logistic regressions were performed to calculate odds ratios (OR) and confidence limits (CL) and to control for possible confounders. Our data provide no evidence for an association between prostate cancer and CAG repeat length. However, we found a significant influence of the ARE-I PSA polymorphism on prostate cancer risk, when calculating the combination of the A/G and G/G genotypes relative to subjects with the A/A genotype (OR = 0.63; 95% CL 0.39-4.99; P = 0.048), suggesting that the G allele has a protective effect. In a case analysis according to Gleason score, the PSA G/G genotype was significantly more frequent in patients with Gleason score >7 (35.1%) than in patients with Gleason score <7 (21.5%), providing evidence that the PSA G/G genotype is associated with more advanced disease at time of diagnosis. However, the ambivalent role of the PSA during prostate carcinogenesis needs further investigation.
引用
收藏
页码:1647 / 1651
页数:5
相关论文
共 35 条
[1]   THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479
[2]   Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia [J].
Bousema, JT ;
Bussemakers, MJG ;
van Houwelingen, KP ;
Debruyne, FMJ ;
Verbeek, ALM ;
de la Rosette, JJMCH ;
Kiemeney, LA .
EUROPEAN UROLOGY, 2000, 37 (02) :234-238
[3]  
BROWN CJ, 1989, AM J HUM GENET, V44, P264
[4]   THE LENGTH AND LOCATION OF CAG TRINUCLEOTIDE REPEATS IN THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN AFFECT TRANSACTIVATION FUNCTION [J].
CHAMBERLAIN, NL ;
DRIVER, ED ;
MIESFELD, RL .
NUCLEIC ACIDS RESEARCH, 1994, 22 (15) :3181-3186
[5]   PROSTATE-CANCER AND THE ANDROGEN RECEPTOR [J].
COETZEE, GA ;
ROSS, RK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :872-873
[6]   BIOLOGICAL EFFECTS OF PROSTATE-SPECIFIC ANTIGEN AS AN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 PROTEASE [J].
COHEN, P ;
PEEHL, DM ;
GRAVES, HCB ;
ROSENFELD, RG .
JOURNAL OF ENDOCRINOLOGY, 1994, 142 (03) :407-415
[7]   (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population [J].
Correa-Cerro, L ;
Wöhr, G ;
Häussler, J ;
Berthon, P ;
Drelon, E ;
Mangin, P ;
Fournier, G ;
Cussenot, O ;
Kraus, P ;
Just, W ;
Paiss, T ;
Cantú, JM ;
Vogel, W .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (03) :357-362
[8]   GENETIC-VARIATION AT 5 TRIMERIC AND TETRAMERIC TANDEM REPEAT LOCI IN 4 HUMAN-POPULATION GROUPS [J].
EDWARDS, A ;
HAMMOND, HA ;
JIN, L ;
CASKEY, CT ;
CHAKRABORTY, R .
GENOMICS, 1992, 12 (02) :241-253
[9]  
Edwards SM, 1999, INT J CANCER, V84, P458, DOI 10.1002/(SICI)1097-0215(19991022)84:5<458::AID-IJC2>3.0.CO
[10]  
2-Y